Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study
reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-wegovy-cuts-heart-risk-by-57-versus-rival-lilly-weight-loss-drug-2025-08-31/
Photo: reuters.com · view article
Wegovy Outperforms Lilly Drugs in Heart Risk ReductionIn a study of 21,000+ patients, Wegovy cut heart attack and death risk by 57% within 3.8 months versus rival weight-loss drugs.
Key FactsAug 31, 2025 · Reading time: ~30 sec.
Summary created with AI assistance · Source: reuters.com
Summary created with AI assistance · Source: reuters.com
- Wegovy lowered the risk of heart attack, stroke, or death by 57% compared to Eli Lilly’s Mounjaro and Zepbound.
- The comparison used real-world data from over 21,000 overweight patients with cardiovascular disease but without diabetes.
- Major adverse heart events occurred in just 0.1% of Wegovy users, significantly fewer than the 0.4% in tirzepatide recipients.
- Presented at the European Society of Cardiology, the findings highlight differing cardiovascular benefits among GLP-1 medications.
Story Details
| Last Updated | |
| Total Articles | 2 |
Main Topics
Similar to This
Previous
Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the 'weight loss Olympics'
cnbc.com/2026/03/06/zealand-stock-zela-roche-trial-weight-loss-ceo-novo-glp1.html
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
cnbc.com/2026/02/24/novo-nordisk-to-slash-wegovy-ozempic-us-list-prices-by-up-to-50percent.html
Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
reuters.com/business/media-telecom/novos-wegovy-ozempic-us-advertising-spend-doubles-rival-eli-lilly-data-shows-2026-01-28/
US FDA requests removal of suicide warnings from weight-loss drugs: The U.S. health regulator on Tuesday asked drugmakers to remove label warnings about a ...
edition.cnn.com/2026/01/13/health/weight-loss-drugs-suicide-risk-warning-removal
FDA Approves Wegovy Weight Loss Pill: How It Compares to Injectables: The weight loss drug Wegovy is now available as a tablet in more than 70,000 U.S ...
healthline.com/health-news/fda-approves-wegovy-weight-loss-pill
Key FactsWegovy Now Available as Daily Weight-Loss Pill
Jan 5, 2026 · Reading time: ~30 sec.
Summary created with AI assistance · Source: cnn.com
Summary created with AI assistance · Source: cnn.com
- The 1.5 mg starter dose of Wegovy is now accessible as a daily pill with a prescription.
- For self-paying patients, the pill is generally less expensive than the weekly injection priced at $349 per month.
- Wegovy also reduces the risk of heart attack and stroke in overweight adults with established heart disease.
- Clinical trials indicate the pill produces comparable weight loss and side effects to the injectable version.
Novo Nordisk rolls out $349 Wegovy cash price ahead of plan: Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a ...
reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-rolls-out-349-wegovy-cash-price-ahead-plan-2025-11-17/
Weight loss drug Wegovy becomes cheaper in India, slashes price by up to 37%: Here’s how much it costs now
financialexpress.com/life/health/weight-loss-drug-wegovy-becomes-cheaper-in-india-slashes-price-by-up-to-37-heres-how-much-it-costs-now/4040461/
Trump strikes deal to lower cost of Wegovy, Zepbound weight loss drugs: Trump said his administration reached an agreement with Novo Nordisk and Eli Lilly to ...
nbcnews.com/health/health-news/trump-weight-loss-drugs-cost-wegovy-zepbound-novo-nordisk-eli-lilly-rcna242309
Novo Nordisk strikes US Medicare price deal: Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide ...
reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-accepts-ozempic-wegovy-rybelsus-prices-us-medicare-negotiations-2025-11-05/
Novo Nordisk share in focus: Eli Lilly attacks Novo Nordisk with new factory: The competition for supremacy in the booming market for obesity therapies is ...
finanzen.net/nachricht/aktien/abnehm-tabletten-novo-nordisk-aktie-im-blick-rivale-eli-lilly-verschaerft-konkurrenzkampf-mit-neuem-werk-14883167
Exclusive: Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts
reuters.com/business/world-at-work/novo-nordisk-cuts-us-obesity-education-team-layoffs-begin-say-sources-online-2025-09-18/
Danish pharmaceutical giant Novo Nordisk to cut 5,000 jobs in Denmark: Pharmaceutical giant Novo Nordisk announced on Wednesday that it would cut 11 percent of ...
thelocal.dk/20250910/danish-pharmaceutical-giant-novo-nordisk-to-cut-5000-jobs-in-denmark
Key FactsNovo Nordisk Cuts 9,000 Jobs Amid Rising Competition
Sep 10, 2025 · Reading time: ~45 sec.
Summary created with AI assistance · Source: reuters.com
Summary created with AI assistance · Source: reuters.com
- Novo Nordisk will eliminate 9,000 positions, equal to 11.5% of its workforce, including 5,000 cuts in Denmark.
- This restructuring is expected to save about $1.3 billion per year and streamline decision-making processes.
- New CEO Mike Doustdar plans to foster a performance-driven culture and prioritize investments in key therapy areas.
- The company now forecasts operating profit growth between 4% and 10% for 2025, down from earlier estimates.
Sometimes the hardest decisions are the right ones for the future we're building.— Mike Doustdar, CEO of Novo Nordisk, discussing the necessity of tough decisions for the long-term success of the company.
STOXX 600 ends higher on defence boost; Novo Nordisk jumps after Wegovy data: European shares finished marginally higher on Monday, supported by defence stocks ...
reuters.com/markets/europe/stoxx-600-ends-higher-defence-boost-novo-nordisk-jumps-after-wegovy-data-2025-09-01/
Novo Nordisk shares rise: Wegovy outperforms Eli Lilly drug: According to Novo Nordisk, Wegovy reduces the risk of heart attack, stroke, or sudden death by 57 ...
finanzen.net/nachricht/aktien/herzgesundheit-novo-nordisk-aktie-in-gruen-wegovy-zeigt-bessere-kardiovaskulaere-wirkung-als-eli-lilly-mittel-14787314
Novo Nordisk earnings disappoint amid fierce competition
dlvr.it/TML2gs
Novo Nordisk slides further on US competition, new CEO concerns: Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent ...
reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-slides-further-us-competition-new-ceo-concerns-2025-07-30/
Key FactsNovo Nordisk Cuts Forecast, Doustdar Named New CEO
Jul 30, 2025 · Reading time: ~45 sec.
Summary created with AI assistance · Source: smh.com.au
Summary created with AI assistance · Source: smh.com.au
- Novo Nordisk’s market value fell by US$70 billion, or $107 billion, as its 2025 sales-growth forecast was cut to 8–14 per cent from 13–21 per cent.
- Maziar Mike Doustdar was named the new CEO and is due to take up the role on August 7, after joining Novo Nordisk in 1992.
- The shares initially plunged nearly 30 per cent, were down more than 20 per cent by mid-afternoon and had fallen 44 per cent over the year.
- In the United States, Eli Lilly’s weekly Zepbound prescriptions surpassed Wegovy’s by more than 100,000 this year, while at least one million people continue to use compounded GLP-1 drugs.
The stock has gone from being a market darling to one of its biggest letdowns.— Angelo Meda, portfolio manager and head of equities at Banor SIM in Milan, commented on Novo Nordisk's stock performance.
Major insurance changes are coming to GLP-1 drugs for weight loss. Here’s how that could affect patients
cnn.com/2025/07/01/health/zepbound-wegovy-insurance-cvs-bcbs-weight-loss
Novo Nordisk’s Wegovy, the blockbuster weight loss drug, debuts in India: How much will it cost, who needs it, key benefits
indianexpress.com/article/health-wellness/wegovy-the-global-weight-loss-drug-launched-in-india-how-much-will-it-cost-10085043/
Eli Lilly’s Mounjaro gets marketing approval for weight-loss and diabetes treatment in India
financialexpress.com/business/industry-eli-lillys-mounjaro-gets-marketing-approval-for-weight-loss-and-diabetes-treatment-in-india-3893554/
Novo Nordisk's stellar Wegovy-fuelled run of hiking sales guidance could be ending
reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-stellar-wegovy-fuelled-run-hiking-sales-guidance-could-be-ending-2025-04-24/
Key FactsNovo Nordisk: Wegovy Sales May Stagnate
Apr 24, 2025 · Reading time: ~45 sec.
Summary created with AI assistance · Source: reuters.com
Summary created with AI assistance · Source: reuters.com
- Novo Nordisk may lower its 2025 sales forecast due to plateauing Wegovy prescriptions and increased competition from Eli Lilly's Zepbound.
- Analysts expect the guidance to be cut to 14%-22%, marking the slowest growth since 2021.
- Novo's market value has dropped by 45% since December, raising concerns about its competitiveness in the obesity drug market.
- The FDA has given pharmacies until May 22 to stop producing compounded versions of Wegovy, which may boost demand for Novo's products.
I am very cautious on Novo. I definitely see the possibility of a guidance cut.— Lukas Leu, portfolio manager at Bellevue Asset Management, which owns Novo shares.
Next